Vaccine platform recombinant measles viruses | Pandemic PACT Tracker

Key facts

Disease
N/A
Start & end year
2021
2026
Known Financial Commitments (USD)
$601,096.08
Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
Principal Investigator
N/A
Research Location
Germany
Lead Research Institution
Paul-Ehrlich-Institut Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
Research Priority Alignment
N/A

Research Category
14
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.